Please select the option that best describes you:
Topics:
General Internal Medicine • Rheumatology • Rheumatoid Arthritis • Interstitial lung disease • Pulmonology • Diffuse Parenchymal Lung Disease • CTD-ILD
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Answer from: at Academic Institution
The available literature on abatacept and tocilizumab in RA-ILD does not provide a definitive answer and hopefully with the general increase in interest in ILD we will have more definitive data in the near future. My review of the current literature suggests that abatacept has a slightly higher perc...
Sign in or Register to read more
Answer from: at Academic Institution
There are no known factors that predict treatment response to specific immunomodulatory agents such as tocilizumab or abatacept.